Tubulis GmbH
The goal of this clinical study is to learn more about the study drug TUB-040, safety, tolerability, pharmacokinetics (PK), and effectiveness in treating patients with unresectable or metastatic non-small cell lung cancer (NSCLC). The primary objectives of this study are to determine the safety and tolerability and effectiveness of TUB-040, and/or recommended Phase 2 dose (RP2D).
Key Inclusion Criteria: 1. Adults, male or nonpregnant, nonbreastfeeding female, age ≥18 years at the date of consent. 2. Eastern Cooperative Oncology Group performance status of 0 or 1. 3. Documented radiographic progression on or after the most recent line of anticancer therapy. 4. Life expectancy of more than 12 weeks for disease-related mortality as evaluated by the INV. 5. At least 1 radiologically measurable lesion by RECIST v1.1, which can include a lesion in an irradiated field that shows progression according to RECIST v1.1. 6. Stable metastases to the central nervous system (CNS) ar…
Administered IV
Arctuva estimate
Verify or correct the compensation shown for this listing.